, San Mateo, CA, and King Pharmaceuticals, Inc., Bristol, TN). In a previous study, the Opioid Attractiveness Technology Scaling (OATS) method identified, from a drug abuser’s point of view, the particular features of a prescription opioid relevant to its attractiveness for recreational use. A second online
sample rated the extent to which these features applied to particular products they had actually used/abused. These see more data were used to model the abusers’ overall preference for prescription opioids they had used/abused.
Design. In the present study, this method was applied to a not-yet-marketed ADF using substance abuse counselors as proxies for prescription opioid abusers. Thirty-eight counselors were given materials describing the new ADF along with four known products.
Results. Thirty-two counselors demonstrated
sufficient agreement with abusers’ ratings of the overall attractiveness of these drugs. The overall model yielded a significant pseudo R(2) of 0.15 (P < 0.001), with increasing model fit based on preferred route of administration, from swallowing whole (pseudo R(2) = 0.06; P < 0.001) and best for those who preferred to inject (pseudo R(2) = 0.40; P < 0.001). Data from a cross-validation group of 16 counselors/proxies were used to calculate the OATS scores for the five rated drugs and revealed significant differences between the ADF and OxyContin (R) (Purdue Pharma LP, DZNeP mw Stamford, CT), Percocet (R) (Endo Pharmaceuticals, selleck products Chadds
Ford, PA), and Vicodin (R) (Abbott Laboratories, Abbott Park, IL), but not Talwin (R) NX (Sanofi-aventis, Bridgewater, NJ), which was identified in the prior study as a highly unattractive drug for recreational purposes.
Conclusions. The OATS method shows promise for providing pre-marketing estimates of attractiveness for abuse of not-yet-marketed ADFs.”
“Background
Tumor of the temporal bone is a rare disease with a very poor prognosis. Surgery and postoperative radiotherapy are usually the recommended treatments for squamous cell carcinoma (SCC) of the external and middle ear, which may cause conductive hearing loss. The purpose of this study was to evaluate the audiologic results and compliance of active middle ear implant (AMEI) and establish the feasibility of the procedure in a patient treated for middle ear cancer.
Methods
A 73-year-old patient treated with lateral petrosectomy, neck dissection, reconstruction/obliteration by pedicled pectoralis major myocutaneous flap, and postoperative full dose radiotherapy for external and middle ear SCC was selected for AMEI. Preoperative audiometric and speech audiometry tests were performed on both ears before and after the activation.
Main Outcome Measures
Pure tone free field audiometry. Binaural free field speech audiogram.
Results
Aided pure tone free field audiometry AMEI results show an increase in air conduction.